Sean Marett. BioNTech
July 9, 2019 05:05 AM EDTUpdated 05:25 AM
Financing

Ger­man can­cer biotech BioN­Tech rais­es a mam­moth $325M in lat­est round, bring­ing to­tal haul to $1.4B+

Natalie Grover

Reporter

With sev­en clin­i­cal as­sets, a string of key part­ner­ships with ti­tans of the phar­ma­ceu­ti­cal in­dus­try and whis­pers about a po­ten­tial IPO, Ger­man can­cer drug de­vel­op­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times